Company / Capital Expenditures
Aquestive Therapeutics, Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$562.0K
FY2025
5-year range
$159.0K / $1.0M
FY2021-FY2025
Trend
+253.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +253% YoY in FY2025, a notable deviation from the 7-year average annual change of +24%.
Based on SEC 10-K filings.
$562,000 in FY2025 with a 5-year CAGR of -3.3%.
Declined from $995,000 to $562,000 over the past 2 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -18.1%
- 5-Year CAGR
- -3.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.3%, indicating a declining trend.
- In FY2025, capital expenditures increased 253.5% year-over-year.
- Peak capital expenditures was recorded in FY2018.
- Lowest capital expenditures in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $562.0K | +253.5% |
| FY2024 | $159.0K | -84.0% |
| FY2023 | $995.0K | -2.8% |
| FY2022 | $1.0M | +98.1% |
| FY2021 | $517.0K | -22.0% |
| FY2020 | $663.0K | -63.7% |
| FY2019 | $1.8M | -11.8% |
| FY2018 | $2.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026